

Clinical Policy: Agalsidase Beta (Fabrazyme)

Reference Number: ERX.SPA.104

Effective Date: 10.01.16

Last Review Date: 05.20

Line of Business: Commercial, Medicaid

[Revision Log](#)

See **Important Reminder** at the end of this policy for important regulatory and legal information.

Description

Agalsidase beta (Fabrazyme[®]) is a recombinant human alpha-galactosidase A enzyme.

FDA Approved Indication(s)

Fabrazyme is indicated for use in patients with Fabry disease.

Policy/Criteria

Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

Health plan approved formularies should be reviewed for all coverage determinations. Requirements to use preferred alternative agents apply only when such requirements align with the health plan approved formulary.

It is the policy of health plans affiliated with Envolve Pharmacy Solutions[™] that Fabrazyme is **medically necessary** when the following criteria are met:

I. Initial Approval Criteria

A. Fabry Disease (must meet all):

1. Diagnosis of Fabry disease confirmed by one of the following (a or b):
 - a. Enzyme assay demonstrating a deficiency of alpha-galactosidase activity;
 - b. DNA testing;
2. Age ≥ 8 years;
3. Dose does not exceed 1 mg per kg every 2 weeks.

Approval duration: 6 months

B. Other diagnoses/indications

1. Refer to ERX.PA.01 if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized).

II. Continued Therapy

A. Fabry Disease (must meet all):

1. Currently receiving medication via a health plan affiliated with Envolve Pharmacy Solutions or member has previously met initial approval criteria;
2. Member is responding positively to therapy as evidenced by improvement in the individual member's Fabry disease manifestation profile (*see Appendix D for examples*);
3. If request is for a dose increase, new dose does not exceed 1 mg per kg every 2 weeks.

Approval duration: 12 months

B. Other diagnoses/indications (must meet 1 or 2):

1. Currently receiving medication via a health plan affiliated with Envolve Pharmacy Solutions and documentation supports positive response to therapy.
Approval duration: Duration of request or 6 months (whichever is less); or
2. Refer to ERX.PA.01 if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized).

III. Diagnoses/Indications for which coverage is NOT authorized:

- A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off-label use policy – ERX.PA.01 or evidence of coverage documents.

IV. Appendices/General Information

Appendix A: Abbreviation/Acronym Key

FDA: Food and Drug Administration

Appendix B: Therapeutic Alternatives

Not applicable

Appendix C: Contraindications/Boxed Warnings

None reported

Appendix D: General Information

The presenting symptoms and clinical course of Fabry disease can vary from one individual to another. As such, there is not one generally applicable set of clinical criteria that can be used to determine appropriateness of continuation of therapy. Some examples, however, of improvement in Fabry disease as a result of Fabrazyme therapy may include improvement in:

- Fabry disease signs such as pain in the extremities, hypohidrosis or anhidrosis, or angiokeratomas;
- Diarrhea, abdominal pain, nausea, vomiting, and flank pain;
- Renal function;
- Neuropathic pain, heat and cold intolerance, vertigo and diplopia;
- Fatigue.

V. Dosage and Administration

Indication	Dosing Regimen	Maximum Dose
Fabry disease	1 mg/kg IV every 2 weeks	1 mg/kg/2 weeks

VI. Product Availability

Single-use vial: 5 mg, 35 mg

VII. References

1. Fabrazyme Prescribing Information. Cambridge, MA: Genzyme Corporation; December 2018. Available at <http://www.fabrazyme.com>. Accessed February 4, 2020.
2. Ortiz A, Germain DP, Desnick RJ, et al. Fabry disease revisited: management and treatment recommendations for adult patients. *Molecular Genetics and Metabolism* 2018;123:416-27.
3. Hopkin RJ, Jeffries JL, Laney DA, et al. The management and treatment of children with Fabry disease: A United States-based perspective. *Molecular Genetics and Metabolism* 2016;117:104-13.

Reviews, Revisions, and Approvals	Date	P&T Approval Date
Policy split from USS.SPMN.33 Lysosomal Storage Disorders and converted to new template. Added age restriction per PI. Removed requirement for all patients to have clinical signs/symptoms and requirement for female patients to have substantial disease manifestations.	08.16	09.16
Converted to new template. Added prescriber requirement. Modified age restriction from > 8 years to ≥ 8 years per PI. Added max dose criteria. Added requirement for positive response to therapy.	06.17	08.17
4Q17 Annual Review Removed prescriber requirement.	09.11.17	11.17

Reviews, Revisions, and Approvals	Date	P&T Approval Date
2Q 2018 annual review: No significant changes. References reviewed and updated.	02.26.18	05.18
2Q 2019 annual review: no significant changes; references reviewed and updated.	02.27.19	05.19
2Q 2020 annual review: no significant changes; references reviewed and updated.	02.04.20	05.20

Important Reminder

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information.

This Clinical Policy is not intended to dictate to providers how to practice medicine, nor does it constitute a contract or guarantee regarding payment or results. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members.

This policy is the property of Envolve Pharmacy Solutions. Unauthorized copying, use, and distribution of this Policy or any information contained herein is strictly prohibited. By accessing this policy, you agree to be bound by the foregoing terms and conditions, in addition to the Site Use Agreement for Health Plans associated with Envolve Pharmacy Solutions.

©2016 Envolve Pharmacy Solutions. All rights reserved. All materials are exclusively owned by Envolve Pharmacy Solutions and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Envolve Pharmacy Solutions. You may not alter or remove any trademark, copyright or other notice contained herein.